Details of the Drug

General Information of Drug (ID: DM2AR7L)

Drug Name

Meloxicam

Synonyms

Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica

Indication

Disease Entry	ICD 11	Status	REF
Arthritis	FA20	Approved	[1]
Osteoarthritis	FA00-FA05	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

351.4

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5C6 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 89% [3]
Clearance: The total clearance of drug is 0.42C0.48 L/h [5]
Elimination: 0.25% of drug is excreted from urine in the unchanged form, and 1.6% of the parent drug is excreted in the feces [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 20 hours [6]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.71143 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.003% [8]
Vd: The volume of distribution (Vd) of drug is 10-15 L [9]
Water Solubility: The ability of drug to dissolve in water is measured as 0.012 mg/mL [4]

Chemical Identifiers

Formula: C14H13N3O4S2
IUPAC Name: 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
Canonical SMILES: CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
InChI: InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
InChIKey: ZRVUJXDFFKFLMG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 54677470
ChEBI ID: CHEBI:6741
CAS Number: 71125-38-7
DrugBank ID: DB00814
TTD ID: D0G7FJ
VARIDT ID: DR00199
INTEDE ID: DR1020
ACDINA ID: D00393

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[12]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[14]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Drug Response	[15]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[14]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[16]
L-selectin (SELL)	OT6RAJZR	LYAM1_HUMAN	Gene/Protein Processing	[17]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Gene/Protein Processing	[14]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Gene/Protein Processing	[18]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Arthritis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	2.08E-01	1.68E-03	0.03
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	4.79E-01	-1.88E-02	-1.73E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	5.93E-01	-5.40E-02	-2.92E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.76E-01	-4.64E-01	-9.16E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Meloxicam

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Dexamethasone.	Rheumatoid arthritis [FA20]	[20]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Meloxicam and Leflunomide.	Rheumatoid arthritis [FA20]	[21]
-----------

Coadministration of a Drug Treating the Disease Different from Meloxicam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Meloxicam and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[22]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Meloxicam and Repaglinide.	Acute diabete complication [5A2Y]	[23]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Meloxicam and Glibenclamide.	Acute diabete complication [5A2Y]	[23]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Meloxicam and Tolazamide.	Acute diabete complication [5A2Y]	[23]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Meloxicam and Glipizide.	Acute diabete complication [5A2Y]	[23]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Meloxicam caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[24]
Inotersen	DMJ93CT	Major	Increased risk of bleeding by the combination of Meloxicam and Inotersen.	Amyloidosis [5D00]	[24]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Meloxicam and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[25]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Meloxicam and Cilostazol.	Arterial occlusive disease [BD40]	[26]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Budesonide.	Asthma [CA23]	[20]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Meloxicam and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Kanamycin.	Bacterial infection [1A00-1C4Z]	[28]
Sulfamethoxazole	DMB08GE	Moderate	Decreased metabolism of Meloxicam caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS stimulant effects by the combination of Meloxicam and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Streptomycin.	Bacterial infection [1A00-1C4Z]	[28]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Meloxicam and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Meloxicam and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Meloxicam and ABT-492.	Bacterial infection [1A00-1C4Z]	[27]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Netilmicin.	Bacterial infection [1A00-1C4Z]	[28]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Meloxicam and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS stimulant effects by the combination of Meloxicam and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Etidronic acid.	Bone paget disease [FB85]	[29]
Risedronate	DM5FLTY	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Risedronate.	Bone paget disease [FB85]	[29]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Meloxicam and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[30]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Meloxicam caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Meloxicam and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[26]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Meloxicam and Iodipamide.	Cholelithiasis [DC11]	[32]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Meloxicam and Levomilnacipran.	Chronic pain [MG30]	[33]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Meloxicam and Regorafenib.	Colorectal cancer [2B91]	[24]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Meloxicam and Drospirenone.	Contraceptive management [QA21]	[34]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Methoxyflurane.	Corneal disease [9A76-9A78]	[24]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Meloxicam and Ardeparin.	Coronary thrombosis [BA43]	[35]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Meloxicam caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[36]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Meloxicam caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[37]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Meloxicam caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[38]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Meloxicam caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[39]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Meloxicam and Danaparoid.	Deep vein thrombosis [BD71]	[35]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Meloxicam and Rivaroxaban.	Deep vein thrombosis [BD71]	[40]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Meloxicam and Sertraline.	Depression [6A70-6A7Z]	[33]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Meloxicam and Vilazodone.	Depression [6A70-6A7Z]	[33]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Meloxicam and Vortioxetine.	Depression [6A70-6A7Z]	[33]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Meloxicam and Milnacipran.	Depression [6A70-6A7Z]	[33]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Meloxicam and Escitalopram.	Depression [6A70-6A7Z]	[33]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Meloxicam and Clomipramine.	Depression [6A70-6A7Z]	[33]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Meloxicam and Cannabidiol.	Epileptic encephalopathy [8A62]	[24]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Meloxicam when combined with Ethacrynic acid.	Essential hypertension [BA00]	[41]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Meloxicam and Tazemetostat.	Follicular lymphoma [2A80]	[26]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Meloxicam and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[24]
Sulfinpyrazone	DMEV954	Moderate	Decreased metabolism of Meloxicam caused by Sulfinpyrazone mediated inhibition of CYP450 enzyme.	Gout [FA25]	[22]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Meloxicam when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[41]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Meloxicam when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[41]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Meloxicam caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[42]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Meloxicam and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[43]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Meloxicam caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Meloxicam caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[22]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Meloxicam and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[45]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Meloxicam and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[21]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Meloxicam and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[46]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Meloxicam when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[41]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Meloxicam when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[47]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Meloxicam and Dipyridamole.	Hypertension [BA00-BA04]	[26]
Balsalazide	DM7I1T9	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Balsalazide.	Indeterminate colitis [DD72]	[48]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Meloxicam caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[22]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Meloxicam and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[49]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Meloxicam and Idelalisib.	Mature B-cell leukaemia [2A82]	[50]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Meloxicam and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[51]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Meloxicam and Ibrutinib.	Mature B-cell lymphoma [2A85]	[52]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Meloxicam and Ponatinib.	Mature B-cell lymphoma [2A85]	[53]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Meloxicam caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[24]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Meloxicam and Exjade.	Mineral absorption/transport disorder [5C64]	[54]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Meloxicam and Panobinostat.	Multiple myeloma [2A83]	[22]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Deflazacort.	Muscular dystrophy [8C70]	[20]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Meloxicam and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[26]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Meloxicam and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[55]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Meloxicam and Prasugrel.	Myocardial infarction [BA41-BA43]	[24]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Meloxicam and Vorapaxar.	Myocardial infarction [BA41-BA43]	[56]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Meloxicam and Sibutramine.	Obesity [5B80-5B81]	[33]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Meloxicam and Dexfenfluramine.	Obesity [5B80-5B81]	[33]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Meloxicam when combined with Polythiazide.	Oedema [MG29]	[41]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Meloxicam caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[57]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Meloxicam and MK-4827.	Ovarian cancer [2C73]	[24]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Aspirin.	Pain [MG30-MG3Z]	[58]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Meloxicam caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[59]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Meloxicam caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[60]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Meloxicam caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[61]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Meloxicam and Epoprostenol.	Pulmonary hypertension [BB01]	[62]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Meloxicam and Iloprost.	Pulmonary hypertension [BB01]	[62]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Meloxicam and Everolimus.	Renal cell carcinoma [2C90]	[63]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Meloxicam and Temsirolimus.	Renal cell carcinoma [2C90]	[63]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Meloxicam and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[27]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Meloxicam caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[20]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Meloxicam and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[20]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Meloxicam and Pitolisant.	Somnolence [MG42]	[24]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Meloxicam caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[64]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Meloxicam and Caplacizumab.	Thrombocytopenia [3B64]	[26]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Meloxicam and Apixaban.	Thrombosis [DB61-GB90]	[24]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Meloxicam and Cangrelor.	Thrombosis [DB61-GB90]	[26]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Meloxicam and Brilinta.	Thrombosis [DB61-GB90]	[24]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Meloxicam and Cabozantinib.	Thyroid cancer [2D10]	[65]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Meloxicam and Sirolimus.	Transplant rejection [NE84]	[63]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Meloxicam and Tacrolimus.	Transplant rejection [NE84]	[63]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Meloxicam and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[23]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Meloxicam and Olsalazine.	Ulcerative colitis [DD71]	[48]
Cinoxacin	DM4EWNS	Moderate	Additive CNS stimulant effects by the combination of Meloxicam and Cinoxacin.	Urinary tract infection [GC08]	[27]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Meloxicam and Betrixaban.	Venous thromboembolism [BD72]	[66]
-----------


⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearate	E00453	2724691	Emulsifying agent; Gelling agent; Glidant; Modified-release agent; Stiffening agent; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Pigment red 5	E00380	82169	Colorant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Meloxicam 10 mg capsule	10 mg	Oral Capsule	Oral
Meloxicam 5 mg capsule	5 mg	Oral Capsule	Oral
Meloxicam 15 mg tablet	15 mg	Oral Tablet	Oral
Meloxicam 7.5 mg tablet	7.5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7220).
2	Meloxicam FDA Label
3	FDA Approved Drug Products: ZYNRELEF (bupivacaine and meloxicam) solution
4	BDDCS applied to over 900 drugs
5	FDA approved products: Mobic (meloxicam) oral tablets
6	A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol. 1996 Apr;35 Suppl 1:13-6. doi: 10.1093/rheumatology/35.suppl_1.13.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18.
10	Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7.
11	Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
14	Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
15	Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
16	Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
17	Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem. 2002 Oct 11;277(41):38212-21. doi: 10.1074/jbc.M205142200. Epub 2002 Jul 29.
18	Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):85-94.
19	Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
20	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
21	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
22	Cerner Multum, Inc. "Australian Product Information.".
23	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
24	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
26	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
27	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
28	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
29	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
30	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
31	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
32	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
33	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
34	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
35	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
36	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
37	Cerner Multum, Inc. "Canadian Product Information.".
38	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
39	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
40	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
41	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
42	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
43	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
44	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
45	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
46	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
47	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
48	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
49	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
50	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
51	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
52	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
53	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
54	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
55	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
56	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
57	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
58	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
59	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
60	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
61	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
62	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
63	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
64	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
65	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
66	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.